

Gavin Giovannoni

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/2392053/publications.pdf](https://exaly.com/author-pdf/2392053/publications.pdf)

Version: 2024-02-01

367
papers

28,796
citations

10475

72
h-index

6540

158
g-index

430
all docs

430
docs citations

430
times ranked

23312
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2006, 354, 899-910.	30.1	2,982
2	Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2012, 367, 1098-1107.	30.1	1,529
3	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017, 376, 221-234.	30.1	1,424
4	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017, 376, 209-220.	30.1	1,402
5	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2012, 380, 1819-1828.	12.1	1,062
6	A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2010, 362, 416-426.	30.1	827
7	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet, The</i> , 2018, 391, 1263-1273.	12.1	726
8	Meta-analysis of early nonmotor features and risk factors for Parkinson disease. <i>Annals of Neurology</i> , 2012, 72, 893-901.	5.8	626
9	Recommended Standard of Cerebrospinal Fluid Analysis in the Diagnosis of Multiple Sclerosis. <i>Archives of Neurology</i> , 2005, 62, 865-70.	4.5	498
10	Multiple sclerosis: risk factors, prodromes, and potential causal pathways. <i>Lancet Neurology, The</i> , 2010, 9, 727-739.	10.4	467
11	Neurofilament light chain. <i>Neurology</i> , 2015, 84, 2247-2257.	1.1	439
12	Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. <i>Lancet Neurology, The</i> , 2009, 8, 254-260.	10.4	438
13	Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases. <i>PLoS ONE</i> , 2013, 8, e75091.	2.5	395
14	Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. <i>Nature Medicine</i> , 2007, 13, 492-497.	30.1	334
15	Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. <i>Brain</i> , 2003, 126, 2191-2202.	8.0	333
16	Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. <i>JAMA Neurology</i> , 2020, 77, 1132.	9.3	317
17	Brain health: time matters in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 9, S5-S48.	2.1	303
18	Is it time to target no evident disease activity (NEDA) in multiple sclerosis?. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 329-333.	2.1	286

#	ARTICLE	IF	CITATIONS
19	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2013, 381, 2167-2175.	12.1	270
20	An Updated Meta-Analysis of Risk of Multiple Sclerosis following Infectious Mononucleosis. <i>PLoS ONE</i> , 2010, 5, e12496.	2.5	265
21	Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2018, 379, 1017-1027.	30.1	254
22	Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1594-1604.	3.3	249
23	Alemtuzumab CARE-MS II 5-year follow-up. <i>Neurology</i> , 2017, 89, 1117-1126.	1.1	238
24	Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. <i>EBioMedicine</i> , 2017, 16, 41-50.	6.0	230
25	Smoking and Multiple Sclerosis: An Updated Meta-Analysis. <i>PLoS ONE</i> , 2011, 6, e16149.	2.5	228
26	Human Endogenous Retroviruses in Neurological Diseases. <i>Trends in Molecular Medicine</i> , 2018, 24, 379-394.	7.1	222
27	Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. <i>Lancet Neurology, The</i> , 2011, 10, 329-337.	10.4	207
28	Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab. <i>JAMA Neurology</i> , 2017, 74, 961.	9.3	205
29	The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. <i>Journal of Neurology</i> , 2009, 256, 405-415.	3.8	201
30	Alemtuzumab CARE-MS I 5-year follow-up. <i>Neurology</i> , 2017, 89, 1107-1116.	1.1	194
31	Poststreptococcal acute disseminated encephalomyelitis with basal ganglia involvement and auto-reactive antibasal ganglia antibodies. <i>Annals of Neurology</i> , 2001, 50, 588-595.	5.8	191
32	Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies. <i>Trends in Molecular Medicine</i> , 2020, 26, 296-310.	7.1	188
33	Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 298-304.	6.0	175
34	Serum neurofilament is associated with progression of brain atrophy and disability in early MS. <i>Neurology</i> , 2017, 88, 826-831.	1.1	175
35	Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. <i>Practical Neurology</i> , 2015, 15, 273-279.	1.6	171
36	Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology, The</i> , 2016, 15, 259-269.	10.4	169

#	ARTICLE	IF	CITATIONS
37	Infectious causes of multiple sclerosis. <i>Lancet Neurology</i> , The, 2006, 5, 887-894.	10.4	165
38	Optimizing treatment success in multiple sclerosis. <i>Journal of Neurology</i> , 2016, 263, 1053-1065.	3.8	159
39	Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. <i>Neurology</i> , 2015, 84, 1639-1643.	1.1	158
40	The COVID-19 pandemic and the use of MS disease-modifying therapies. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 102073.	2.1	157
41	Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 273-279.	6.0	153
42	Multiple sclerosis: the environment and causation. <i>Current Opinion in Neurology</i> , 2007, 20, 261-268.	3.7	144
43	The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 162-166.	3.3	142
44	“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1179-1187.	3.3	134
45	Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm. <i>Current Opinion in Neurology</i> , 2018, 31, 233-243.	3.7	132
46	COVID-19 Vaccine Response in People with Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 89-100.	5.8	131
47	Fingolimod modulates microglial activation to augment markers of remyelination. <i>Journal of Neuroinflammation</i> , 2011, 8, 76.	7.4	128
48	Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2019, 18, 845-856.	10.4	126
49	UK consensus on pregnancy in multiple sclerosis: “Association of British Neurologists” guidelines. <i>Practical Neurology</i> , 2019, 19, 106-114.	1.6	124
50	Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. <i>Journal of Neurology</i> , 2018, 265, 1199-1209.	3.8	121
51	Switching from natalizumab to fingolimod. <i>Neurology</i> , 2015, 85, 29-39.	1.1	112
52	Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 153-160.	2.1	112
53	Smouldering multiple sclerosis: the “real MS”. <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642110667.	3.8	106
54	Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 29, 168-174.	2.1	102

#	ARTICLE	IF	CITATIONS
55	Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom. <i>BMC Public Health</i> , 2020, 20, 912.	3.0	101
56	Cladribine to Treat Relapsing Forms of Multiple Sclerosis. <i>Neurotherapeutics</i> , 2017, 14, 874-887.	4.7	100
57	Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects. <i>Drugs</i> , 2021, 81, 207-231.	11.1	100
58	Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 29, 157-167.	2.1	99
59	The Multiple Sclerosis Care Unit. <i>Multiple Sclerosis Journal</i> , 2019, 25, 627-636.	3.3	98
60	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309690.	6.0	97
61	Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 12, 70-78.	2.1	97
62	Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 565-573.	6.0	94
63	Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. <i>Lancet Neurology</i> , The, 2020, 19, 214-225.	10.4	94
64	PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 31-37.	6.0	93
65	Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2008, 193, 120-129.	2.4	91
66	Neurofilament ELISA validation. <i>Journal of Immunological Methods</i> , 2010, 352, 23-31.	1.4	91
67	Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 202-218.	2.1	90
68	No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis. <i>Advances in Therapy</i> , 2014, 31, 1134-1154.	3.0	84
69	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. <i>Lancet Neurology</i> , The, 2014, 13, 472-481.	10.4	84
70	Multiple sclerosis: a practical overview for clinicians. <i>British Medical Bulletin</i> , 2010, 95, 79-104.	6.9	80
71	HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 9-12.	6.0	79
72	Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641985498.	3.8	79

#	ARTICLE	IF	CITATIONS
73	No laughing matter: subacute degeneration of the spinal cord due to nitrous oxide inhalation. <i>Journal of Neurology</i> , 2018, 265, 1089-1095.	3.8	78
74	Disposable MMP-9 sensor based on the degradation of peptide cross-linked hydrogel films using electrochemical impedance spectroscopy. <i>Biosensors and Bioelectronics</i> , 2015, 68, 660-667.	10.4	75
75	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2020, 19, 988-997.	10.4	75
76	BMI and low vitamin D are causal factors for multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.8	75
77	The clinical significance of an intrathecal monoclonal immunoglobulin band. <i>Neurology</i> , 2003, 60, 1163-1166.	1.1	73
78	e-Health and multiple sclerosis: An update. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1657-1664.	3.3	71
79	Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005, 165, 41-52.	2.4	70
80	Parkinson's disease determinants, prediction and gene-environment interactions in the UK Biobank. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1046-1054.	6.0	68
81	Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. <i>Journal of Neurology</i> , 2013, 260, 2297-2305.	3.8	67
82	The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102174.	2.1	64
83	Siponimod and Cognition in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 96, e376-e386.	1.1	64
84	Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 29-38.	2.1	63
85	International consensus on quality standards for brain health-focused care in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1809-1818.	3.3	63
86	Editors' welcome and a working definition for a multiple sclerosis cure. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 65-67.	2.1	62
87	PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 219-226.	4.3	62
88	Cladribine: mechanisms and mysteries in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1266-1271.	6.0	62
89	Systematic review and meta-analysis of the association between Epstein-Barr virus, multiple sclerosis and other risk factors. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1281-1297.	3.3	62
90	Assessing treatment response to interferon- β . <i>Neurology</i> , 2014, 82, 248-254.	1.1	61

#	ARTICLE	IF	CITATIONS
91	Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. <i>Neurology</i> , 2016, 87, 1985-1992.	1.1	59
92	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. <i>Lancet Neurology</i> , The, 2022, 21, 608-619.	10.4	58
93	Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFN γ in multiple sclerosis patients. <i>Journal of Immunological Methods</i> , 2008, 336, 113-118.	1.4	57
94	Evaluating more naturalistic outcome measures. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e162.	6.8	57
95	Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS). <i>Multiple Sclerosis Journal</i> , 2015, 21, 57-66.	3.3	56
96	Post-streptococcal autoimmune dystonia with isolated bilateral striatal necrosis. <i>Developmental Medicine and Child Neurology</i> , 2002, 44, 485-489.	2.7	55
97	The implications of immunogenicity for protein-based multiple sclerosis therapies. <i>Journal of the Neurological Sciences</i> , 2008, 275, 7-17.	0.6	54
98	Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 939-948.	3.3	53
99	Bradykinesia-Akinesia Incoordination Test: Validating an Online Keyboard Test of Upper Limb Function. <i>PLoS ONE</i> , 2014, 9, e96260.	2.5	53
100	Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 274-278.	6.0	52
101	Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 819-827.	3.3	52
102	The bradykinesia akinesia incoordination test (BRAIN TEST $\frac{1}{2}$), an objective and user-friendly means to evaluate patients with Parkinsonism. <i>Movement Disorders</i> , 2000, 15, 641-647.	4.3	51
103	Multiple Sclerosis Cerebrospinal Fluid Biomarkers. <i>Disease Markers</i> , 2006, 22, 187-196.	1.4	51
104	Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 9, 36-46.	2.1	51
105	Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression. <i>PLoS ONE</i> , 2013, 8, e70019.	2.5	50
106	The importance of a multi-disciplinary perspective and patient activation programmes in MS management. <i>Multiple Sclerosis Journal</i> , 2016, 22, 34-46.	3.3	50
107	Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. <i>Multiple Sclerosis Journal</i> , 2018, 24, 222-226.	3.3	50
108	Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate. <i>International Journal of MS Care</i> , 2015, 17, 236-243.	1.0	50

#	ARTICLE	IF	CITATIONS
109	MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. <i>Journal of Neurology</i> , 2013, 260, 1136-1146.	3.8	49
110	Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1862-1870.	3.3	49
111	The effects of intrathecal rituximab on biomarkers in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 6, 49-53.	2.1	48
112	Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628561775336.	3.8	47
113	Epstein-Barr virus and multiple sclerosis: association or causation?. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 287-297.	2.8	46
114	Elevated salivary protein in Parkinson's disease and salivary DJ-1 as a potential marker of disease severity. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1251-1255.	2.2	46
115	Vitamin D supplementation. <i>Practical Neurology</i> , 2018, 18, 35-42.	1.6	45
116	Genetic Background Can Result in a Marked or Minimal Effect of Gene Knockout (GPR55 and CB2). <i>Trends in Neurosciences</i> , 2013, 8, e76907.	2.5	44
117	Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune tolerance promoting CD8 T cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis. <i>Immunology</i> , 2017, 150, 444-455.	4.4	44
118	Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. <i>BMJ Open</i> , 2018, 8, e021944.	2.1	44
119	Screening performance of abbreviated versions of the UPSIT smell test. <i>Journal of Neurology</i> , 2019, 266, 1897-1906.	3.8	44
120	Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102135.	2.1	44
121	Therapies for multiple sclerosis: considerations in the pediatric patient. <i>Nature Reviews Neurology</i> , 2011, 7, 109-122.	10.0	43
122	Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids. <i>Journal of Neuroimmune Pharmacology</i> , 2015, 10, 281-292.	4.0	43
123	Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis. <i>Brain</i> , 2018, 141, 2834-2847.	8.0	43
124	Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. <i>Annals of Neurology</i> , 2018, 84, 527-536.	5.8	43
125	Protecting people with multiple sclerosis through vaccination. <i>Practical Neurology</i> , 2020, 20, 435.1-445.	1.6	43
126	Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. <i>BMC Neurology</i> , 2016, 16, 117.	1.8	42

#	ARTICLE	IF	CITATIONS
127	Switching patients at high risk of PML from natalizumab to another disease-modifying therapy. <i>Practical Neurology</i> , 2016, 16, 389-393.	1.6	41
128	Protease-activated receptor-1 activation by granzyme B causes neurotoxicity that is augmented by interleukin-1 β . <i>Journal of Neuroinflammation</i> , 2017, 14, 131.	7.4	41
129	Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102572.	2.1	41
130	Social determinants of health in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2022, 18, 723-734.	10.0	41
131	A brief history of NEDA. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 228-230.	2.1	40
132	The diagnostic criteria for multiple sclerosis: From Charcot to McDonald. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 9-14.	2.1	39
133	Immunogenicity and tolerability of an investigational formulation of interferon- β 1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. <i>Clinical Therapeutics</i> , 2007, 29, 1128-1145.	2.3	38
134	Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis. <i>Brain</i> , 2014, 137, 92-108.	8.0	38
135	Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. <i>Journal of Neuroimmunology</i> , 2021, 357, 577627.	2.4	38
136	Gene-Environment Interactions in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.8	37
137	Effects of Delayed-Release Dimethyl Fumarate (DMF) on Health-Related Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies. <i>Clinical Therapeutics</i> , 2014, 36, 1958-1971.	2.3	36
138	Increased expression of colony-stimulating factor-1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss. <i>Glia</i> , 2018, 66, 2108-2125.	5.3	36
139	Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population. <i>JAMA Neurology</i> , 2022, 79, 359.	9.3	36
140	Validating a novel web-based method to capture disease progression outcomes in multiple sclerosis. <i>Journal of Neurology</i> , 2013, 260, 2505-2510.	3.8	35
141	Neural cell adhesion molecules in brain plasticity and disease. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 13-20.	2.1	35
142	Cytokine profiles show heterogeneity of interferon- β response in multiple sclerosis patients. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e202.	6.8	35
143	Epstein-Barr virus, latitude and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 362-365.	3.3	34
144	Natalizumab reduces relapse clinical severity and improves relapse recovery in MS. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 705-711.	2.1	34

#	ARTICLE	IF	CITATIONS
145	Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsingâ€“Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies. <i>Neurology and Therapy</i> , 2016, 5, 45-57.	3.5	34
146	Epstein-Barrâ€“negative MS: a true phenomenon?. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e318.	6.8	34
147	Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1355-1362.	3.3	33
148	Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 181-183.	2.1	33
149	Alemtuzumab depletion failure can occur in multiple sclerosis. <i>Immunology</i> , 2018, 154, 253-260.	4.4	33
150	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731876064.	1.1	33
151	The RebifÂ® New Formulation Story. <i>Drugs in R and D</i> , 2007, 8, 335-348.	2.2	32
152	Cerebrospinal fluid analysis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 122, 681-702.	0.3	32
153	Control of spasticity in a multiple sclerosis model using central nervous systemâ€“excluded CB ₁ cannabinoid receptor agonists. <i>FASEB Journal</i> , 2014, 28, 117-130.	0.5	32
154	Neuroprotection in a Novel Mouse Model of Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e79188.	2.5	32
155	Antineuronal antibody status and phenotype analysis in Tourette's syndrome. <i>Movement Disorders</i> , 2007, 22, 1424-1429.	4.3	31
156	A practical review of the neuropathology and neuroimaging of multiple sclerosis. <i>Practical Neurology</i> , 2016, 16, 279-287.	1.6	31
157	Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon Î²-1a in MS. <i>Neurology</i> , 2016, 87, 1464-1472.	1.1	31
158	A Systematic Review and Mixed Treatment Comparison of Pharmaceutical Interventions for Multiple Sclerosis. <i>Neurology and Therapy</i> , 2020, 9, 359-374.	3.5	31
159	Neural cell adhesion molecule â€” Description of a CSF ELISA method and evidence of reduced levels in selected neurological disorders. <i>Journal of Neuroimmunology</i> , 2010, 225, 118-122.	2.4	30
160	The neurodegenerative prodrome in multiple sclerosis. <i>Lancet Neurology</i> , The, 2017, 16, 413-414.	10.4	30
161	Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon. <i>CNS and Neurological Disorders - Drug Targets</i> , 2012, 11, 610-623.	1.6	30
162	Cladribine tablets for relapsingâ€“remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 49-54.	2.1	29

#	ARTICLE	IF	CITATIONS
163	Multiple sclerosis outpatient future groups: improving the quality of participant interaction and ideation tools within service improvement activities. <i>BMC Health Services Research</i> , 2015, 15, 105.	2.2	29
164	Gender identity disorders and multiple sclerosis risk: A national record-linkage study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1759-1762.	3.3	29
165	Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1367-1376.	3.3	29
166	Peripheral blood neurofilament light chain levels: the neurologist's C-reactive protein?. <i>Brain</i> , 2018, 141, 2235-2237.	8.0	29
167	A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. <i>Neurology</i> , 2020, 95, e1027-e1040.	1.1	29
168	The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 64-75.	2.1	28
169	Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. <i>Clinical Therapeutics</i> , 2017, 39, 1671-1679.	2.3	28
170	Change in pregnancy-associated multiple sclerosis relapse rates over time: a meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102241.	2.1	28
171	Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review. <i>Neurology and Therapy</i> , 2022, 11, 571-595.	3.5	28
172	Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGM study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 483-492.	6.0	27
173	Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis. <i>Acta Neuropathologica Communications</i> , 2013, 1, 84.	5.4	26
174	Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. <i>Multiple Sclerosis Journal</i> , 2014, 20, 464-470.	3.3	26
175	Multiple sclerosis in the Iranian immigrant population of BC, Canada: prevalence and risk factors. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1182-1188.	3.3	26
176	A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 123-128.	2.1	26
177	Cerebrospinal Fluid Biomarkers in Human Spinal Cord Injury from a Phase II Minocycline Trial. <i>Journal of Neurotrauma</i> , 2018, 35, 1918-1928.	3.6	26
178	Enzymatic degradation of <sc>RNA</sc> causes widespread protein aggregation in cell and tissue lysates. <i>EMBO Reports</i> , 2020, 21, e49585.	5.1	26
179	Bone health in chronic neurological diseases: a focus on multiple sclerosis and parkinsonian syndromes. <i>Practical Neurology</i> , 2013, 13, 70-79.	1.6	25
180	Personalized Medicine in Multiple Sclerosis. <i>Neurodegenerative Disease Management</i> , 2017, 7, 13-17.	2.3	25

#	ARTICLE	IF	CITATIONS
181	Expert opinion on the use of cladribine tablets in clinical practice. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642093501.	3.8	25
182	Patient Power Revolution in Multiple Sclerosis: Navigating the New Frontier. <i>Neurology and Therapy</i> , 2018, 7, 179-187.	3.5	24
183	The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies. <i>Frontiers in Immunology</i> , 2020, 11, 124.	4.9	24
184	Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety. <i>Drug Safety</i> , 2020, 43, 635-643.	3.2	24
185	Ethnic and Socioeconomic Associations with Multiple Sclerosis Risk. <i>Annals of Neurology</i> , 2020, 87, 599-608.	5.8	23
186	Strategies to treat and prevent the development of neutralizing anti-interferon- β antibodies. <i>Neurology</i> , 2003, 61, S13-7.	1.1	23
187	Management of Secondary-Progressive Multiple Sclerosis. <i>CNS Drugs</i> , 2004, 18, 653-669.	6.2	22
188	Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1591-1605.	3.3	22
189	Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 14, 46-50.	2.1	21
190	Psychiatric disorders in children with demyelinating diseases of the central nervous system. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1243-1250.	3.3	21
191	Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care. <i>Advances in Therapy</i> , 2019, 36, 3238-3252.	3.0	21
192	Extended dosing of monoclonal antibodies in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2001-2009.	3.3	21
193	The Potential for EBV Vaccines to Prevent Multiple Sclerosis. <i>Frontiers in Neurology</i> , 0, 13, .	2.5	21
194	Science is 1% inspiration and 99% biomarkers. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1442-1452.	3.3	20
195	A multicentre randomised controlled TRIal of IntraVENous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). <i>Health Technology Assessment</i> , 2017, 21, 1-50.	2.9	20
196	CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103448.	2.1	20
197	Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1526-1540.	3.3	20
198	Alcohol Misuse Disorders and Multiple Sclerosis Risk. <i>JAMA Neurology</i> , 2014, 71, 1188.	9.3	19

#	ARTICLE	IF	CITATIONS
199	Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. <i>Journal of Neurology</i> , 2014, 261, 316-323.	3.8	19
200	The role of infections in Behçet disease and neuro-Behçet syndrome. <i>Autoimmunity Reviews</i> , 2015, 14, 609-615.	5.9	19
201	Subtle motor disturbances in PREDICT-PD participants. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 212-217.	6.0	19
202	No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1736-1747.	3.3	19
203	Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5Åmg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies. <i>Advances in Therapy</i> , 2021, 38, 4975-4985.	3.0	19
204	Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 295-302.	6.0	19
205	Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course. <i>International Journal of MS Care</i> , 2012, 14, 105-114.	1.0	19
206	Learning ability correlates with brain atrophy and disability progression in RRMS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 38-43.	6.0	18
207	Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies. <i>Multiple Sclerosis Journal</i> , 2022, 28, 111-120.	3.3	18
208	Chronic lesion activity and disability progression in secondary progressive multiple sclerosis. <i>BMJ Neurology Open</i> , 2022, 4, e000240.	2.0	18
209	Antineuronal antibodies in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 958-963.	4.3	17
210	Natalizumab to fingolimod washout in patients at risk of PML. <i>Neurology</i> , 2014, 82, 1196-1197.	1.1	17
211	Time- and Region-Specific Season of Birth Effects in Multiple Sclerosis in the United Kingdom. <i>JAMA Neurology</i> , 2016, 73, 954.	9.3	17
212	Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1564-1576.	3.3	17
213	Improving estimation of Parkinson's disease risk—the enhanced PREDICT-PD algorithm. <i>Npj Parkinson's Disease</i> , 2021, 7, 33.	5.4	17
214	The Refinement of Genetic Predictors of Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e96578.	2.5	16
215	Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 506-511.	3.7	16
216	Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 20-27.	2.1	16

#	ARTICLE	IF	CITATIONS
217	Dementia risk in a diverse population: A single-region nested case-control study in the East End of London. <i>Lancet Regional Health - Europe</i> , 2022, 15, 100321.	7.8	16
218	Current and Future Role of Interferon Beta in the Therapy of Multiple Sclerosis. <i>Journal of Interferon and Cytokine Research</i> , 2010, 30, 715-726.	1.3	15
219	Individualizing treatment goals and interventions for people with MS. <i>Current Opinion in Neurology</i> , 2012, 25, S20-S27.	3.7	15
220	Multiple sclerosis therapy and Epstein-Barr virus antibody titres. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 372-374.	2.1	15
221	Epstein Barr virus shedding in multiple sclerosis: Similar frequencies of EBV in saliva across separate patient cohorts. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 197-199.	2.1	15
222	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. <i>Multiple Sclerosis Journal</i> , 2022, 28, 842-846.	3.3	15
223	The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 3-5.	2.1	14
224	The "Field Hypothesis": rebound activity after stopping disease-modifying therapies. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 15, A1-A2.	2.1	14
225	Plasma cell and B cell-targeted treatments for use in advanced multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 19-25.	2.1	14
226	Visibility and representation of women in multiple sclerosis research. <i>Neurology</i> , 2019, 92, 713-719.	1.1	14
227	CSF neurofilament light chain testing as an aid to determine treatment strategies in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.8	14
228	Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?. <i>Clinical and Experimental Immunology</i> , 2022, 207, 263-271.	2.7	14
229	A Risk Score for Predicting Multiple Sclerosis. <i>PLoS ONE</i> , 2016, 11, e0164992.	2.5	13
230	The BRAIN test: a keyboard-tapping test to assess disability and clinical features of multiple sclerosis. <i>Journal of Neurology</i> , 2018, 265, 285-290.	3.8	13
231	Serum neurofilament-light concentration and real-world outcome in MS. <i>Journal of the Neurological Sciences</i> , 2020, 417, 117079.	0.6	12
232	COVID-19 vaccines and multiple sclerosis disease-modifying therapies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103155.	2.1	12
233	Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-72.	0.8	12
234	Is EBV the cause of multiple sclerosis?. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103636.	2.1	12

#	ARTICLE	IF	CITATIONS
235	The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103757.	2.1	12
236	Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis. <i>Clinical Drug Investigation</i> , 2012, 32, 15-27.	2.2	11
237	Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanercept. <i>BMC Neurology</i> , 2014, 14, 237.	1.8	11
238	CCSVI-A. A call to clinicians and scientists to vocalise in an Internet age. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 143-146.	2.1	11
239	Women on multiple sclerosis clinical trial steering committees. <i>Annals of Neurology</i> , 2018, 84, 329-330.	5.8	11
240	Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 247-253.	2.1	11
241	Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey. <i>Journal of Medical Internet Research</i> , 2021, 23, e29558.	4.5	11
242	Implications of Low-Titer MOG Antibodies. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103746.	2.1	11
243	Circulating antiganglioside antibodies are not associated with the development of progressive disease or cerebral atrophy in patients with multiple sclerosis. <i>Annals of Neurology</i> , 2000, 47, 684-685.	5.8	10
244	Should we rebrand multiple sclerosis a dementia?. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 12, 79-81.	2.1	10
245	Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 32-40.	2.1	10
246	Estimated and projected burden of multiple sclerosis attributable to smoking and childhood and adolescent high body-mass index: a comparative risk assessment. <i>International Journal of Epidemiology</i> , 2021, 49, 2051-2057.	2.0	10
247	Predicting disability worsening in relapsing and progressive multiple sclerosis. <i>Current Opinion in Neurology</i> , 2021, 34, 312-321.	3.7	10
248	Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110582.	3.8	10
249	Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. <i>Clinical Therapeutics</i> , 2015, 37, 2543-2551.	2.3	9
250	IgG4-related disease: a rare but treatable cause of refractory intracranial hypertension. <i>Practical Neurology</i> , 2016, 16, 235-239.	1.6	9
251	How long is the presymptomatic phase of multiple sclerosis?. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 7, 12-13.	2.1	9
252	Disease modification in advanced MS: Focus on upper limb function. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1956-1957.	3.3	9

#	ARTICLE	IF	CITATIONS
253	Validation of an environmentally-friendly and affordable cardboard 9-hole peg test. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 172-176.	2.1	9
254	No Evident Disease Activityâ€”More Than a Risky Ambition?. <i>JAMA Neurology</i> , 2018, 75, 781.	9.3	9
255	Detecting and predicting neutralization of alemtuzumab responses in MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	6.8	9
256	Predicting Multiple Sclerosis: Challenges and Opportunities. <i>Frontiers in Neurology</i> , 2021, 12, 761973.	2.5	9
257	Towards a global view of multiple sclerosis genetics. <i>Nature Reviews Neurology</i> , 2022, 18, 613-623.	10.0	9
258	Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneity. <i>Biomarkers in Medicine</i> , 2007, 1, 111-119.	1.4	8
259	Promising Emerging Therapies for Multiple Sclerosis. <i>Neurologic Clinics</i> , 2011, 29, 435-448.	1.9	8
260	Serum levels of 25-hydroxy vitamin D in normal Biozzi and C57BL/6 mice and during the course of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE). <i>Inflammation Research</i> , 2013, 62, 659-667.	4.0	8
261	A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 83-84.	2.1	8
262	Social capital: Implications for neurology. <i>Brain and Behavior</i> , 2019, 9, e01169.	2.3	8
263	Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102259.	2.1	8
264	The impact of social capital on patients with multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 58-65.	2.2	8
265	Long-term safety and efficacy of daclizumab beta in relapsingâ€”remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. <i>Journal of Neurology</i> , 2020, 267, 2851-2864.	3.8	8
266	Measuring treatment response to advance precision medicine for multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2166-2173.	3.7	8
267	Exercise training in multiple sclerosis. <i>Lancet Neurology</i> , The, 2022, 21, 313.	10.4	8
268	More to come: Humoral immune responses in MS. <i>Journal of Neuroimmunology</i> , 2011, 240-241, 13-21.	2.4	7
269	Tackling comorbidity in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 144-145.	2.1	7
270	Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study. <i>Journal of Neurology</i> , 2018, 265, 1795-1802.	3.8	7

#	ARTICLE	IF	CITATIONS
271	Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731878376.	1.1	7
272	Health-care disparities for people with multiple sclerosis. Lancet Neurology, The, 2020, 19, 207-208.	10.4	7
273	GloBody Technology: Detecting Anti-Drug Antibody against VH/VL domains. Scientific Reports, 2020, 10, 1860.	3.4	7
274	Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. Journal of Neurology, 2022, 269, 5093-5104.	3.8	7
275	Developing Biomarkers for MS. Current Topics in Behavioral Neurosciences, 2014, 26, 179-194.	0.0	6
276	Web-based assessment of Parkinson's prodromal markers identifies GBA variants. Movement Disorders, 2015, 30, 1002-1003.	4.3	6
277	Time and brain health both matter in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 9, S1-S3.	2.1	6
278	How to refer to people with disease in research outputs: The disconnection between academic practise and that preferred by people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 10, 127-133.	2.1	6
279	Can we afford not to prevent MS-related disability?. Multiple Sclerosis Journal, 2017, 23, 1048-1049.	3.3	6
280	Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies. Acta Neurologica Scandinavica, 2019, 139, 422-427.	2.2	6
281	Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 41, 102024.	2.1	6
282	Severe skin reactions associated with cladribine in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 43, 102140.	2.1	6
283	Gender issues during the times of COVID-19 pandemic. European Journal of Neurology, 2021, 28, e73-e77.	3.6	6
284	Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110576.	3.8	6
285	Derisking CD20-therapies for long-term use. Multiple Sclerosis and Related Disorders, 2022, 57, 103418.	2.1	6
286	The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis. European Journal of Neurology, 2022, 29, 2754-2760.	3.6	6
287	The role of antibody affinity for specific antigens in the differential diagnosis of inflammatory nervous system disorders. Journal of Neuroimmunology, 2006, 180, 29-32.	2.4	5
288	MSer – A new, neutral descriptor for someone with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 31-33.	2.1	5

#	ARTICLE	IF	CITATIONS
289	Complexity of MS management in the current treatment era. <i>Neurology</i> , 2018, 90, 761-762.	1.1	5
290	Prevalence and demographics of multiple sclerosis-associated uveitis: a UK biobank study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102209.	2.1	5
291	World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application. <i>Multiple Sclerosis Journal</i> , 2020, 26, 153-158.	3.3	5
292	Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 922-932.	3.3	5
293	B cell therapy and the use of RNA-based COVID-19 vaccines. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102887.	2.1	5
294	Optimising classification of Parkinson's disease based on motor, olfactory, neuropsychiatric and sleep features. <i>Npj Parkinson's Disease</i> , 2021, 7, 87.	5.4	5
295	Age-specific effects of childhood body mass index on multiple sclerosis risk. <i>Journal of Neurology</i> , 2022, 269, 5052-5060.	3.8	5
296	Multiple sclerosis is one disease. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103961.	2.1	5
297	MSProDiscuss, a Clinical Decision Support Tool for Identifying Multiple Sclerosis Progression. <i>Journal of Clinical Medicine</i> , 2022, 11, 4401.	2.5	5
298	Multiple sclerosis and its pathophysiology. , 2002, , 1606-1619.		4
299	Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways?. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 88-91.	2.1	4
300	Is the 'MS establishment' biased; the case for addressing gender inequality in the field of MS?. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 153-154.	2.1	4
301	Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110242.	1.1	4
302	Can rheumatologists stop causing demyelinating disease?. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103057.	2.1	4
303	Evaluation of remote assessments for multiple sclerosis in an in-home setting. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103125.	2.1	4
304	Remyelination trial failures: Repercussions of ignoring neurorehabilitation and exercise in repair. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103539.	2.1	4
305	Prevalence of disability improvement in relapsing/remitting multiple sclerosis patients treated with cladribine tablets. <i>European Journal of Neurology</i> , 2022, 29, 2144-2147.	3.6	4
306	Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets. <i>Frontiers in Immunology</i> , 2021, 12, 763433.	4.9	4

#	ARTICLE	IF	CITATIONS
307	Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment. <i>Scientific Reports</i> , 2023, 13, .	3.4	4
308	Optimising MS disease-modifying therapies: antibodies in perspective. <i>Journal of Neurology</i> , 2004, 251, v30-v35.	3.8	3
309	The REFLEX study: a missed opportunity?. <i>Lancet Neurology</i> , The, 2012, 11, 22-24.	10.4	3
310	Circulating lymphocyte levels and relationship with infection status in patients with relapsingâ€“remitting multiple sclerosis treated with daclizumab beta. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1725-1736.	3.3	3
311	Do we have equipoise when it comes to how we treat active multiple sclerosis?. <i>Lancet Neurology</i> , The, 2019, 18, 909-911.	10.4	3
312	Inclusion criteria used in trials of people with progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 279-283.	3.3	3
313	Overview of Differences and Similarities of Published Mixed Treatment Comparisons on Pharmaceutical Interventions for Multiple Sclerosis. <i>Neurology and Therapy</i> , 2020, 9, 335-358.	3.5	3
314	Air pollution and multiple sclerosis risk. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102797.	2.1	3
315	Remote testing of vitamin D levels across the UK MS populationâ€“A case control study. <i>PLoS ONE</i> , 2020, 15, e0241459.	2.5	3
316	Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103409.	2.1	3
317	Antibodies to neurofilament light as potential biomarkers in multiple sclerosis. <i>BMJ Neurology Open</i> , 2021, 3, e000192.	2.0	3
318	Safety and efficacy with alemtuzumab over 13â€“years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study. <i>Therapeutic Advances in Neurological Disorders</i> , 2023, 16, .	3.8	3
319	Human swayback disease: expanding the spectrum of diseases associated with abnormal copper metabolism. <i>Journal of Neurology</i> , 2001, 248, 707-707.	3.8	2
320	Simvastatin in patients with progressive multiple sclerosis. <i>Lancet</i> , The, 2014, 384, 952.	12.1	2
321	Systematic review and metaâ€“analysis of salivary protein concentration in <sc>P</sc>arkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1971-1972.	4.3	2
322	Gavin Giovannoni On Why Time Matters in Multiple Sclerosis. <i>Neurodegenerative Disease Management</i> , 2016, 6, 77-79.	2.3	2
323	Why do you have to be lucky to get the MS treatment you deserve?. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 8, A3-A4.	2.1	2
324	Multiple Sclerosis and Demyelinating Diseases. , 2016, , 475-511.		2

#	ARTICLE	IF	CITATIONS
325	How to start a blog. <i>Practical Neurology</i> , 2017, 17, 224-228.	1.6	2
326	Are the high-costs of MS disease-modifying therapies justified?. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, A3-A5.	2.1	2
327	Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1883-1891.	3.3	2
328	Survival: the ultimate long-term outcome in multiple sclerosis. <i>Brain</i> , 2019, 142, 1166-1167.	8.0	2
329	A Cell-Based Assay for the Detection of Neutralizing Antibodies Against Alemtuzumab. <i>BioTechniques</i> , 2020, 68, 185-190.	1.8	2
330	Is multiple sclerosis overdiagnosed?. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102721.	2.1	2
331	Can serum glial fibrillary acidic protein (GFAP) solve the longstanding problem of diagnosis and monitoring progressive multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102931.	2.1	2
332	Side Effects That Occurred Early in People With Multiple Sclerosis During the First Year of Treatment With Cladribine Tablets: A Plain Language Summary. <i>Neurodegenerative Disease Management</i> , 2022, 12, 1-7.	2.3	2
333	EBV and multiple sclerosis: Setting the research agenda. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 67, 104158.	2.1	2
334	Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method. <i>Therapeutic Advances in Neurological Disorders</i> , 2023, 16, .	3.8	2
335	Disease activity 4.5% years after starting cladribine: experience in 264 patients with multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2023, 16, .	3.8	2
336	Increased Urinary Neopterin Excretion in Vaccinated Adults. <i>Pteridines</i> , 1996, 7, 82-86.	0.5	1
337	ECTRIMS 2012: Treatment highlights. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 68-72.	2.1	1
338	Timing is everything in the treatment of multiple sclerosis. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014208960.	0.5	1
339	Should our treatment target in MS include the intrathecal plasma cell response?. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, A1-A2.	2.1	1
340	Distinguishing physiological versus pathological serum NFL levels in multiple sclerosis will require serial measurements. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102477.	2.1	1
341	Ageing and multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101953.	2.1	1
342	Digesting science: Developing educational activities about multiple sclerosis, prevention and treatment to increase the confidence of affected families. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102624.	2.1	1

#	ARTICLE	IF	CITATIONS
343	Amyloidoma mimicking multiple sclerosis. <i>Practical Neurology</i> , 2021, 21, 344-345.	1.6	1
344	Antigen-specific tolerization in human autoimmunity: Inhibition of interferon-beta1a anti-drug antibodies in multiple sclerosis: A case report. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103284.	2.1	1
345	Update on NHS Reset and Reform achievements in 2021. <i>British Journal of Neuroscience Nursing</i> , 2022, 18, S20-S24.	0.2	1
346	How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies?. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103803.	2.1	1
347	Onset of multiple sclerosis is preventable – time to act now!. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 62, 103875.	2.1	1
348	Is it ethical to use teriflunomide as an active comparator in phase 3 trials?. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 78, 104911.	2.1	1
349	Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial. <i>BMJ Open</i> , 2024, 14, e083582.	2.1	1
350	Recent developments in oral medications for the treatment of multiple sclerosis. <i>Future Neurology</i> , 2009, 5, 167-172.	0.5	0
351	Cladribine to treat multiple sclerosis. , 0, , 358-369.		0
352	Emerging disease modifying treatments – A therapeutics update fromECTRIMS/ACTRIMS, Amsterdam, 2011. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 56-58.	2.1	0
353	Corrigendum to – Effects of Delayed-release Dimethyl Fumarate (DMF) on Health-related Quality of Life in Patients With Relapsing-remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies. <i>Clinical Therapeutics</i> , 2018, 40, 812.	2.3	0
354	Is cognitive impairment in multiple sclerosis reversible?. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 23, A1.	2.1	0
355	Chronic-relapsing varicella zoster meningitis – Successfully treated with varicella vaccine. <i>Journal of Infection</i> , 2019, 79, 61-74.	3.4	0
356	The unintended consequences of NICE. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 247-248.	6.0	0
357	Regarding: Nicotinic acetylcholine receptors $\alpha 7$ and $\alpha 9$ modify tobacco smoke risk for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 27, 135245852096994.	3.3	0
358	CLINICAL VIEWPOINT: Immunosuppression and COVID-19. <i>Advances in Clinical Neuroscience & Rehabilitation: ACNR</i> , 2020, 19, 8-9.	0.1	0
359	Dare we mention the C-word?. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102340.	2.1	0
360	It is time to move to alternative clinical trial designs: Reconsidering the holy grail of trial methodology. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103426.	2.1	0

#	ARTICLE	IF	CITATIONS
361	High efficacy treatment is not enough in MS: Socioeconomic factors are key to improving outcomes. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103816.	2.1	0
362	EBV as the "œgluten of MS" hypothesis provides a rationale for trialing antiviral therapies. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 64, 104007.	2.1	0
363	Response: Treatment of multiple sclerosis as a single disease based on the body-pathology-environment model. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 68, 104222.	2.1	0
364	Summary of Research: Collaboration Between Healthcare Professionals and People with Multiple Sclerosis to Develop Communication Tools to Improve the Standard of Multiple Sclerosis Care. <i>Advances in Therapy</i> , 0, , .	3.0	0
365	Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals. <i>Neurology and Therapy</i> , 0, , .	3.5	0
366	Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK. <i>BMJ Open</i> , 2024, 14, e086414.	2.1	0
367	Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2024, 11, .	6.8	0